ACE and hydrops fetalis: Recently, sacubitril/valsartan was approved as a treatment for HFrEF patients as its superior efficacy was demonstrated in the PARADIGM-HF trial conducted in 2015 in terms of reducing mortality and morbidity compared to traditional treatments involving maximal doses of ACE inhibitors [3].